Conventional chemical or biological synthetic methods often encounter challenges in conveniently preparing chiral natural and unnatural products with the same skeleton at a scalable level, due to their complexity with numerous chiral centers or uncharacterized enzymes. Herein, a simplified modular chemoenzymatic platform is designed featuring a streamlined four-enzyme cascade coupled with a chemical module that involves one or two chemical steps. This platform enables the divergent synthesis of structurally diverse natural and unnatural benzylisoquinoline alkaloids (BIAs), including 1-benzylisoquinoline, protoberberine, morphinan, and aporphine alkaloids. Moreover, the enantioselectivity of the chiral BIAs is up to 99% ee. The titer of papaverine reaches an impressive 2.83 g L-1, demonstrating substantial industrial potential. Overall, this work establishes a paradigm for constructing modular chemoenzymatic platforms that simplify the production of structurally diverse natural and unnatural products for drug development.
Liu et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: